search
Back to results

Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation (PUPPVMNI)

Primary Purpose

Respiratory Failure

Status
Completed
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Allevyn Thin®
Askina Transorbent Border®
Linovera®
Sponsored by
B. Braun Medical SA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Respiratory Failure focused on measuring noninvasive mechanical ventilation (NIVM), continuous positive airway pressure (CPAP) ventilation, bilevel positive airway pressure (BIPAP) ventilation, pressure ulcer (PU), nursing assessment

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults (≥18 years).
  • Not tissue injury in face.
  • Not structural deformation of the facial anatomy.

Exclusion Criteria:

  • Rejects Informed Consent

Sites / Locations

  • Emergency and Critical Care. Hospital General Universitario Gregorio Marañón.

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

No Intervention

Active Comparator

Active Comparator

Active Comparator

Arm Label

A-Mask or direct interface

B-Autoadhesive polyurethane dressing

C-Semi-permeable hydrogel-foam

D-Hyper hydrogenated fatty acids

Arm Description

Mask or direct interface

Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.

Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.

Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask. It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.

Outcomes

Primary Outcome Measures

Incidence of PU for each group (mean, standard deviation and quartiles)
Compare the efficacy of the preventive treatments A, B, C and D - previously described-(meaning by efficacy the no occurrence of PU). For definition of PU investigators use the one of the "National Group for the Study and Advice in Pressure Ulcer and Chronic Wounds" (GNEAUPP)

Secondary Outcome Measures

Incidence of total NIVM related PU, by observation registers.
Total incidence of NIVM related PU within the first 24 hours after the withdrawal of the treatment, registered for the different preventive procedures.
Efficiency of preventive measures for PU related to NIVM, by registering incidence and resources invested -time in hours and consumables in euros- (mean, standard deviation and quartiles for each group)
Compare the efficacy and efficiency (cost related efficacy) of the preventive treatments A, B, C and D - previously described

Full Information

First Posted
August 6, 2015
Last Updated
August 15, 2015
Sponsor
B. Braun Medical SA
Collaborators
Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Rey Juan Carlos
search

1. Study Identification

Unique Protocol Identification Number
NCT02526862
Brief Title
Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation
Acronym
PUPPVMNI
Official Title
Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation. Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
February 2012 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
B. Braun Medical SA
Collaborators
Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Rey Juan Carlos

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to test direct application of the Non-Invasive Mechanical Ventilation -NIVM- mask or interface as the most efficient intervention to prevent Pressure Ulcers (PU), compared with other three usual preventive measures which consist in the use of three different medical devices.
Detailed Description
Non-Invasive Mechanical Ventilation (NIVM) has turned into a standard in the care of patients with acute respiratory failure. Defined as a support modality to the patient's spontaneous ventilation, it does not use invasive techniques to ventilate, working as an external device named interface or mask, avoiding so the complications associated to the invasive ventilation. NIVM had been restricted to ICU and Pneumology services, but in the last years it has been extended to ER with good results and it is being also used in the pre-hospital attention and in the home care of chronic patient. Often, the preferred interface is the oronasal, worst tolerated but associated to best treatment of the acute pathology. In most cases to avoid air leaks, its proper placement generates high pressure on the skin, being able to harm patient's tissues, so that this therapy as intervention for the acute patient has pressure ulcers -PU- as main iatrogenic effect - although 95% of the PU are considered as preventable-. To diminish the pressure of the mask on the points of the face, nurses protect the most exposed zones with dressings of hydrogel-foam, polyurethane and/or hyperoxygenated fatty acids, trying to prevent PU. Reviewed studies present a big variability in these practices as well as high dispersion of the results achieved. Preventive measures are different and even none, as applying the mask or the interface directly could be the most effective treatment in the prevention of PU, avoiding not justified increase of fungible and other resources consumption. The aim of this study is to test direct application of the mask or interface, as the most efficient intervention, compared with other three usual preventive measures which consist in the use of three different medical devices: autoadhesive polyurethane dressing (Allevyn Thin®), semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®) or hyperoxygenated fatty acids (Linovera®)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Respiratory Failure
Keywords
noninvasive mechanical ventilation (NIVM), continuous positive airway pressure (CPAP) ventilation, bilevel positive airway pressure (BIPAP) ventilation, pressure ulcer (PU), nursing assessment

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
152 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A-Mask or direct interface
Arm Type
No Intervention
Arm Description
Mask or direct interface
Arm Title
B-Autoadhesive polyurethane dressing
Arm Type
Active Comparator
Arm Description
Protection of the dermis with autoadhesive polyurethane dressing (Allevyn Thin®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
Arm Title
C-Semi-permeable hydrogel-foam
Arm Type
Active Comparator
Arm Description
Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing (Askina Transorbent Border®). The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
Arm Title
D-Hyper hydrogenated fatty acids
Arm Type
Active Comparator
Arm Description
Protection of the dermis with hyper hydrogenated fatty acids (Linovera®) in the contact areas with the NIVM interface or mask. It will apply with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
Intervention Type
Device
Intervention Name(s)
Allevyn Thin®
Intervention Description
Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
Intervention Type
Device
Intervention Name(s)
Askina Transorbent Border®
Intervention Description
Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
Intervention Type
Device
Intervention Name(s)
Linovera®
Intervention Description
Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
Primary Outcome Measure Information:
Title
Incidence of PU for each group (mean, standard deviation and quartiles)
Description
Compare the efficacy of the preventive treatments A, B, C and D - previously described-(meaning by efficacy the no occurrence of PU). For definition of PU investigators use the one of the "National Group for the Study and Advice in Pressure Ulcer and Chronic Wounds" (GNEAUPP)
Time Frame
First 24 hours after the withdrawal of the treatment
Secondary Outcome Measure Information:
Title
Incidence of total NIVM related PU, by observation registers.
Description
Total incidence of NIVM related PU within the first 24 hours after the withdrawal of the treatment, registered for the different preventive procedures.
Time Frame
24 hours after the withdrawal of the treatment
Title
Efficiency of preventive measures for PU related to NIVM, by registering incidence and resources invested -time in hours and consumables in euros- (mean, standard deviation and quartiles for each group)
Description
Compare the efficacy and efficiency (cost related efficacy) of the preventive treatments A, B, C and D - previously described
Time Frame
24 hours after the withdrawal of the treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years). Not tissue injury in face. Not structural deformation of the facial anatomy. Exclusion Criteria: Rejects Informed Consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Peña-Otero, M.Sc.
Organizational Affiliation
Nurse. Emergency and Critical Care. Hospital General Universitario Gregorio Marañón. Nursing Faculty. Universidad Rey Juan Carlos. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Emergency and Critical Care. Hospital General Universitario Gregorio Marañón.
City
Madrid
ZIP/Postal Code
28007
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation

We'll reach out to this number within 24 hrs